ARTICLE | Clinical News

Fzd8-Fc: Phase Ib started

February 24, 2014 8:00 AM UTC

OncoMed began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate OMP-54F28 plus carboplatin and paclitaxel in about 20 patients with recurrent platinum-sensitive ovarian cancer. OMP-54F28 is also being evaluated in a Phase Ib trial in combination with Abraxane nab-paclitaxel and gemcitabine to treat pancreatic cancer and a Phase Ib trial in combination with Nexavar sorafenib in patients with first-line locally advanced or metastatic hepatocellular carcinoma (HCC). OncoMed and Bayer AG (Xetra:BAYN, Leverkusen, Germany) are partnered under a 2010 deal to discover and develop antibodies, proteins and small molecules targeting the Wnt signaling pathway to treat cancer. Under the deal, Bayer has an option to an exclusive license for OMP-54F28 at any point up to the completion of Phase I testing (see BioCentury, June 21, 2010 & Nov. 4, 2013). ...